Regulation of TFPI function by protein S

Summary.  Protein S is an anticoagulant cofactor of full‐length tissue factor pathway inhibitor (TFPI) that facilitates optimal factor Xa‐inhibition and efficient down‐regulation of thrombin generation in plasma. Protein S and TFPI are constitutively active in plasma and therefore provide an effective anticoagulant barrier against unwanted procoagulant activity in the circulation. In this review, we describe the current status on how TFPI‐activity depends on protein S, and show that TFPI and protein S are major regulators of thrombin generation both in the absence and presence of activated protein C (APC). As there is covariation of plasma TFPI and protein S levels both in health and in disease, these findings suggest that the risk of venous thrombosis associated with protein S deficiency states might be in part explained by the accompanying low plasma TFPI levels.

[1]  J. Griffin,et al.  The Thrombin-sensitive Region of Protein S Mediates Phospholipid-dependent Interaction with Factor Xa* , 2008, Journal of Biological Chemistry.

[2]  T. Hackeng,et al.  Regulation of coagulation by protein S , 2008, Current opinion in hematology.

[3]  Jason R. Cruz,et al.  Detailed Mechanisms of the Inactivation of Factor VIIIa by Activated Protein C in the Presence of Its Cofactors, Protein S and Factor V* , 2008, Journal of Biological Chemistry.

[4]  G. Broze,et al.  Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa–tissue factor , 2008, Journal of thrombosis and haemostasis : JTH.

[5]  B. Dahlbäck,et al.  Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. , 2008, Blood.

[6]  F. Rosendaal,et al.  The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1 , 2008, Journal of thrombosis and haemostasis : JTH.

[7]  R. van Oerle,et al.  Coagulation factors and the protein C system as determinants of thrombin generation in a normal population , 2007, Journal of thrombosis and haemostasis : JTH.

[8]  F. Rosendaal,et al.  Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography , 2007, Thrombosis and Haemostasis.

[9]  P. García de Frutos,et al.  Molecular basis of protein S deficiency , 2007, Thrombosis and Haemostasis.

[10]  B. Dahlbäck.  The tale of protein S and C4b-binding protein, a story of affection , 2007, Thrombosis and Haemostasis.

[11]  J. Rosing,et al.  Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  G. Willems,et al.  Protein S multimers are generated in vitro and affect protein S structure-function analyses. , 2006, Seminars in hematology.

[13]  E. Minar,et al.  Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism , 2005, Thrombosis and Haemostasis.

[14]  F. Rosendaal,et al.  Determinants of the APTT‐ and ETP‐based APC sensitivity tests , 2005, Journal of thrombosis and haemostasis : JTH.

[15]  J. Rosing,et al.  Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance. , 2004, Blood.

[16]  S. Rezende,et al.  Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. , 2004, Blood.

[17]  F. Rosendaal,et al.  Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. , 2003, Blood.

[18]  G. Willems,et al.  Purified protein S contains multimeric forms with increased APC-independent anticoagulant activity. , 2001, Biochemistry.

[19]  P. Mannucci,et al.  Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis , 2001, British journal of haematology.

[20]  E. Thulin,et al.  EGF-like module pair 3-4 in vitamin K-dependent protein S: modulation of calcium affinity of module 4 by module 3, and interaction with factor X. , 1999, Journal of molecular biology.

[21]  A. Sagripanti,et al.  Tissue factor pathway inhibitor. , 1999, Minerva medica.

[22]  G. Broze,et al.  Regulation of Extrinsic Pathway Factor Xa Formation by Tissue Factor Pathway Inhibitor* , 1998, The Journal of Biological Chemistry.

[23]  G. Broze,et al.  Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. , 1997, Blood.

[24]  A. Mast,et al.  Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. , 1996, Blood.

[25]  H. Hemker,et al.  Effects of Protein S and Factor Xa on Peptide Bond Cleavages during Inactivation of Factor Va and Factor VaR506Q by Activated Protein C (*) , 1995, The Journal of Biological Chemistry.

[26]  G. Broze,et al.  Tissue Factor Pathway Inhibitor , 1995, Thrombosis and Haemostasis.

[27]  K. Duffin,et al.  Heterogeneity of plasma tissue factor pathway inhibitor. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[28]  A. Lindahl,et al.  The present status of tissue factor pathway inhibitor. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[29]  R. Wesselschmidt,et al.  Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. , 1992, Blood.

[30]  L. S. Nielsen,et al.  The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. , 1991, Biochemistry.

[31]  D. Rader,et al.  Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. , 1991, Blood.

[32]  Susan G. Brown,et al.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.